Loading
A phase 1/2 trial of AZD0486, Prednisone, Rituximab in chronic lymphocytic leukaemia and mantle cell lymphoma, run by AstraZeneca, now recruiting.
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies is a phase 1/2 interventional study registered as NCT06564038 by AstraZeneca, with 408 participants planned, started 2025-01-30 and due to reach its primary completion in 2029-06-11. Interventions recorded: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine. Conditions listed: Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares AZD0486, Hodgkin lymphoma, AstraZeneca, Non-Hodgkin lymphoma (all types).
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide.
Shares AZD0486, Chronic lymphocytic leukaemia, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/